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ARTICLE
Small molecule inhibitors of RAS-effector protein
interactions derived using an intracellular antibody
fragment
Camilo E. Quevedo1, Abimael Cruz-Migoni 1,2, Nicolas Bery1, Ami Miller1, Tomoyuki Tanaka3,8, Donna Petch3,
Carole J.R. Bataille4, Lydia Y.W. Lee5, Phillip S. Fallon5, Hanna Tulmin1,9, Matthias T. Ehebauer1,10,
Narcis Fernandez-Fuentes 2,6, Angela J. Russell4, Stephen B. Carr2,7, Simon E.V. Phillips 2,7 &
Terence H. Rabbitts1
Targeting specific protein–protein interactions (PPIs) is an attractive concept for drug
development, but hard to implement since intracellular antibodies do not penetrate cells and
most small-molecule drugs are considered unsuitable for PPI inhibition. A potential solution
to these problems is to select intracellular antibody fragments to block PPIs, use these
antibody fragments for target validation in disease models and finally derive small molecules
overlapping the antibody-binding site. Here, we explore this strategy using an anti-mutant
RAS antibody fragment as a competitor in a small-molecule library screen for identifying
RAS-binding compounds. The initial hits are optimized by structure-based design, resulting in
potent RAS-binding compounds that interact with RAS inside the cells, prevent RAS-effector
interactions and inhibit endogenous RAS-dependent signalling. Our results may aid RAS-
dependent cancer drug development and demonstrate a general concept for developing small
compounds to replace intracellular antibody fragments, enabling rational drug development
to target validated PPIs.
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There are at least two problem areas in devising therapeuticsto intracellular targets in disease. Most are not enzymesper se for which active site inhibitors can be derived, but
rather their function is mediated by specific protein–protein
interactions (PPIs)1. This has led to the development of macro-
molecules like intracellular antibody fragments2–4 (herein refer-
red to as macrodrugs, distinct from conventional drugs)5 that fold
and interact with targets in the intracellular environment and can
blockade PPI due to higher relative affinity scores compared with
natural PPI partner6. Thus intracellular antibodies or peptide
aptamers7 can easily be selected with high affinity and be used for
target validation by interrogating relevant preclinical models for
effects on the specific disease, such as a mutant RAS in cancer3.
However, devising methods to internalize these macrodrugs into
cells to achieve the function has been elusive. Small-molecule
drugs have opposite innate properties to macrodrugs. They can
readily penetrate cells, but they are thought to lack the ability to
interfere with PPIs because of low affinity and low surface area
interaction8–10, although examples of compounds with effects
against PPI have been described in recent years11,12. One way to
bring together these various properties is to use macrodrugs that
have been used for target validation to select small compounds
that bind to the target at the same location and which would thus
have the potential for hit to lead drug development (macrodrugs
include a variety of macromolecules, ranging for instance from
oligonucleotides, to mRNA to proteins). Human intracellular
single-domain antibody fragments have been well characterised
since the first example13. The binding site of a variable region
domain comprises about 600 Å2 14 and is the minimal region of
an antibody-binding site recognizing an antigen15. This is a very
small region equivalent to less than 500 daltons16 and can narrow
down the protein target area in competition screenings. Searching
in smaller areas will increase the chances of detecting small
molecules (within the Lipinski rules17) with similar properties as
the previously validated antibody fragments.
The RAS family of proteins is among the most frequently
mutated in human cancers18,19, with KRAS mutations found in
almost all pancreatic tumours, about 40% of colorectal tumours
and about 30% of lung adenocarcinomas20 http://cancer.sanger.
ac.uk/cosmic. Reagents that block these RAS-effector interactions
have thus far largely been macromolecules ranging from cyclic
peptides21 to antibodies22,23 or antibody fragments3,4 and, from a
number of approaches targeting the RAS family of proteins with
small compounds24–32, only two have shown direct RAS-effector
interface inhibition31,32. We have characterized an antibody
fragment, using intracellular antibody capture technology33,34,
that specifically binds to the activated forms of HRAS, KRAS and
NRAS with optimal binding properties (low Kd, high Kon and low
Koff) and inhibits tumour growth in xenograft models35 even
when mutations in other proteins are present in the cells3.
Crystallisation with the antibody fragment yielded an scFv-
HRASG12V crystal complex, where the binding site of the anti-
body fragment was identified and its RAS-effector inhibitory
properties were understood36.
Here, we employ the intracellular antibody to identify a com-
pound from a chemical fragment library that binds to RAS pro-
teins adjacent to the effector binding region. High-resolution
crystal structures show the binding of this compound to mutant
RAS, and this structural information facilitates hit to lead
development. Our structure-based approach has produced com-
pounds that bind to mutant KRAS with sub-μM affinity that
interfere with RAS-effector PPI and endogenous RAS-dependent
signalling in human cancer cells, and show a correlation between
in vitro binding and potency in the cells. Our work demonstrates
that intracellular antibody fragments can be used as progenitors
in drug development programmes to arrive at high-affinity
compounds binding to mutant KRAS. This approach can be
generalised to any PPI in a disease.
Results
SPR with anti-RAS antibody identifies RAS-binding com-
pounds. The initial SPR screening strategy is outlined in Fig. 1a–c,
in which compounds from a fragment-based, small-molecule
library were counter-screened for the binding to GTP-bound
(Fig. 1a) or GDP-bound (Fig. 1b) HRAS. The chemical fragment
library, comprising 656 compounds, was screened using a BIAcore
T100 with single-point analysis of each compound at 200 μM
(Fig. 1d). Putative RAS-binding compounds were individually re-
tested using GST-HRASG12V-GTPγS and wild-type GST-HRAS-
GDP. One compound, out of 26 initial hits, with a quinoline core
(Abd-1) showed preferential binding to HRASG12V-GTPγS
(Fig. 1e, g). The dose response of Abd-1 (3 to 2000 μM range) was
tested in cSPR using immobilized GST-HRASG12V-GTPγS, GST-
HRASG12V-GDP or GST-HRASG12V-GTPγS-anti-RAS single
chain Fv (scFv)3 (Fig. 1e–g). Abd-1 bound to GST-HRASG12V-
GTPγS with a dose response (Fig. 1e). In contrast, no binding was
observed when HRASG12V was in complex with the anti-RAS scFv
(Fig. 1f) or with the GDP-bound form of HRAS (Fig. 1g). The Kd
for Abd-1 was estimated greater than 370 μM against HRASG12V
GTPγS (Supplementary Fig. 1).
The chemical structure of Abd-1 is shown in Fig. 1
(MW:238.25, clogP 2.33, solubility 140 μM). We sought analogues
with improved biophysical properties and potentially better Kd.
One candidate analogue (Abd-2, Fig. 1h) was identified (Mw
259.26; logP 1.83) with a solubility of 446 μM. Abd-2 has a
benzodioxane bicyclic core with furanyl amide as the right-hand
side of the molecule. SPR analysis showed that compound Abd-2
binds to both HRASG12V-GppNHp and KRASG12V-GppNHp
(Fig. 1h shows KRAS binding). Abd-2 is a racemic mixture and
the enantiomers (compounds Abd-2a and Abd-2b) were tested
for binding to KRASG12V-GppNHp by SPR (Fig. 1i, j). Both
enantiomers bind to KRASG12V with similar properties. A
truncated analogue of Abd-2, designated as Abd-3, also binds
to KRASG12V-GppNHp, but with lower affinity than Abd-2
(Fig. 1k), showing the intrinsic binding properties of the
benzodioxane core.
We measured the dissociation constant of Abd-2 using
waterLOGSY37,38 showing a Kd of 235 μM (Supplementary
Fig. 2). We also confirmed that Abd-2 reproduced preferential
binding to the activated form of KRASG12V-GppNHp compared
with the form KRAS-GDP (Supplementary Fig. 3a) and no longer
binds to KRASG12V-GppNHp in the presence of anti-RAS scFv
(Supplementary Fig. 3b).
Antibody-derived compounds bind to KRAS near the switch
regions. Protein crystallography was used to determine the
KRAS-binding site for Abd-2 and for the truncated analogue
Abd-3. Two different mutant KRAS-GppNHp proteins, G12D
and Q61H were crystallised, and the crystals were soaked with
compounds to yield high-resolution structures (Fig. 2, Supple-
mentary Table 1). Compounds Abd-2 and Abd-3 bind in a pocket
adjacent to the RAS switch regions I and II (Fig. 2a, b) that has
been previously described as a site of other small-molecule
binding24,25,39 Residues lining the binding pocket in KRASQ61H
include K5, L6, V7, S39, D54, I55, L56, Y71 and T74 (Supple-
mentary Fig. 4). Electron density for Abd-2 was identified only
with KRASQ61H-GppNHp (crystal form I) and in five of the six
KRAS molecules in the asymmetric unit (the ligand density in
chain B is used for illustration in Fig. 2a). The electron density is
stronger around the benzodioxane core, with the furanyl amide
substituent less well defined (Fig. 2a). No H-bond interactions
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were observed between the compound and protein, with only van
der Waals contacts with K5, L6, V7, E37, D38, S39, D54, I55, L56,
G70, Y71 and T74. The electron density around furanyl amide
provides an orientation marker for the binding pose of this
compound and also the explanation of the competitive effect of
anti-RAS antibody fragment on its binding (see below).
Analysis of the compound Abd-3–KRASQ61H complex (crystal
form I) shows the best electron density in chain B (Fig. 2b and
Supplementary Fig. 4). The ligand terminal NH3+ makes H-bond
interactions (salt bridge) to D54 carboxylate and to a well-defined
water molecule (430) that is in turn also co-ordinated by an
H-bond to D54 carboxylate and the hydroxyl group of S39. In
contrast, Abd-3 has a rather different binding geometry in the
KRASG12D crystal structure (crystal form II, Fig. 2c), as it is
stabilized by two H-bonds via the ligand terminal NH3+, one
with E37 carboxylate and the other with the main chain carbonyl
oxygen of D119 from a neighbouring protein in the KRASG12D
crystal lattice. Thus, both interactions stabilize the terminal
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–CH2NH3+ functionality in a different orientation from the one
observed for KRASQ61H, but it is directly influenced by the
packing in crystal form II (Fig. 2b, c and Supplementary Table 1).
The mechanism by which the antibody fragment inhibits the
binding of compounds was revealed by comparing the structures
of HRASG12V-Fv3 with KRASG12V-Abd-2 (Fig. 2d). Superimpos-
ing the complexes shows that the CDR2 region of the VH is
oriented towards the binding pocket, where benzodioxane
interacts with the side chain of K56 in CDR2, partly overlapping
with the furanyl substituent (Fig. 2d). Structure analysis shows
that intracellular antibody does not cause structural changes in
HRASG12V(3) and the compound-binding pocket remains
accessible (Supplementary Fig. 5). Therefore the competition
occurs by displacement rather than allosteric changes in RAS
protein.
A chemical series from the antibody-derived compound Abd-2.
The initial hit antibody-derived compound gave us the anchor
binding site on KRAS, from which to develop compounds to
compete with RAS-effector PPIs. A chemical series was developed
and representative structures are shown in Fig. 3a (Abd-4, 5, 6
and 7). High-resolution crystallography showed that all com-
pounds bind in the same hydrophobic pocket near switch I
(Fig. 3b, c and Supplementary Table 2) and with increasing
potency (Supplementary Fig. 6). In the development of the series,
efforts were focussed on the right-hand side (RHS) of the mole-
cule (i.e. substituents of the dioxane), since crystallography con-
sistently showed electron density predominantly around the
benzodioxane core. Compound Abd-4 was extended from the
amide group, but KRASQ61H crystal soaking only showed elec-
tron density in two of the six chains (the ligand density in chain B
is illustrated in Fig. 3, and only around the benzodioxane core
(Fig. 3b, c). No H-bond interactions were observed between the
benzodioxane rings and protein, with only van der Waals con-
tacts with K5, L6, V7, E37, D54, I55, L56, G70, Y71 and T74.
Therefore, efforts were directed to substitutions on the left-hand
side (LHS), on the benzene ring of the benzodioxane main core,
targeting interactions with K5, D54 or S39.
Aromatic substituents at position 8 in Abd-5 increased the
level of electron density observed around the compound, and it
was identified in all six chains of the asymmetric unit (chain F is
illustrated in Fig. 3). Crystal soaking of KRASQ61H with Abd-5
showed the new pyridine ring leading to the side of the switch I
region of KRAS (Fig. 3c). This compound forces D54 to rotate to
allow the third ring to be accommodated in a pocket formed by
S39, Y40, D54, I55 and L56. No H-bond interactions were
identified between Abd-5 and the protein, and the only
interactions identified were van der Waals contacts to K5, L6,
V7, S39, Y40, R41, D54, I55, L56, G70, Y71 and T74. No
interactions were observed from the RHS of the molecule.
Analysis of crystals soaked with Abd-5 indicated that explora-
tion around the pyridine ring in positions 3 to 5 could gain extra
interactions in the KRAS switch I region. Abd-6 included a third
ring (benzene) at position 3 of the pyridine ring in Abd-5 and a
tetrahydropyran-4-carboxamide substituent in place of the
benzamide derivative on the right-hand side (Fig. 3b, c). Soaked
crystals showed electron density for the new aniline-based
functionality, but no H-bond with the protein in any of the four
chains where the compound was identified. The only interactions
observed were van der Waals contacts to K5, L6, V7, S39, Y40,
R41, D54, I55, L56, G70, Y71, T74 and G75, and also with amino
acid residues from a neighbouring protein within the unit cell. The
binding affinities of Abd-5 and Abd-6, measured using NMR-
binding detection method Carr–Purcell–Meiboom–Gill (CPMG),
a relaxation dispersion technique (RD) using proton NMR’s of the
ligand molecule as sensors for binding and unbinding kinetics and
without any isotope labelling. In CPMG, signal reduction occurs
with increased protein concentration40,41. This showed that Abd-5
and Abd-6 had improved affinities of 220 nM and 38 nM
(respectively, Supplementary Fig. 6b and d)
An important feature in Abd-5 and Abd-6 was the lack of
interactions between KRASQ61H and the benzamide derivative
(Abd-5) or the tetrahydropyran-4-carboxamide (Abd-6), sub-
stituted from the original furan group in Abd-2. The RHS of Abd-
6 was removed to reduce the molecular weight, but to maintain or
increase the interaction with the protein. The new analogue, Abd-
7, gave improved crystallography results with full electron density
for the compound (Fig. 3a–c) and with van der Waals contacts to
K5, L6, V7, S39, Y40, R41, D54, I55, L56, G70, Y71, T74 and G75.
Abd-7 was found in five out of six protein chains. Interactions to
residues from a neighbouring protein within the unit cell were
also identified, same as Abd-6.
The protein-binding capabilities of the most potent of this
series of compounds (Abd-5, Abd-6 and Abd-7) was confirmed in
an orthogonal assay (waterLOGSY) using KRASG12V-GppNHp
(Supplementary Fig. 6). The spectra for each compound show
that all the proton peaks have reverse polarity in the presence of
the KRAS protein (Supplementary Fig. 6a, c and e). The values of
220, 38 and 51 nM were found, respectively, for compounds Abd-
5, Abd-6 and Abd-7 (Supplementary Fig. 6b, d, f). The ligand
efficiencies values (each approximated to 0.3), molecular weights
and solubilities for these three compounds are shown in
Supplementary Fig. 6g.
KRAS-binding compounds inhibit RAS PPIs in cell assays. We
have investigated the ability of the chemical series to inhibit RAS-
effector PPI using cell-based assays involving a RAS-effector
BRET2 assay, the effect on downstream biomarker phosphor-
ylation and tumour cell viability. A RAS PPI BRET2 toolbox has
been developed to evaluate the in vivo effect of compounds on
RAS-effector PPI of compounds42. This assay comprises trans-
fection of HEK293T cells with plasmids to express BRET donor
(fusions of either K, N or HRAS, including a carboxy-terminal
farnesylation signal tetrapeptide, with Renilla luciferase variant 8,
Rluc8) and acceptor molecules (fusions of effector proteins with
GFP2), and permits the assessment of inhibitors of RAS-effector
Fig. 1 Competition SPR identifies RAS-binding compounds. a, b The SPR screen involves a differential binding approach to identify compounds binding to
activated, GTP-bound mutant RAS (HRASG12V), but not GDP-bound HRAS, indicated in (a) and (b), respectively. c Schematic representation of the cSPR
approach. Anti-GST polyclonal goat antibody was captured on a CM5 SPR chip, and GST-RAS proteins were captured with anti-GST. Compounds that bind
to a target protein (in this case HRAS) can be challenged with binding to the target protected by the high-affinity antibody fragment. If the binding regions
coincide, the compound will not bind to the target. d A chemical fragment library of 656 compounds was initially screened as single points at 200mM
using in the four channels (Fc) of a Biacore T100: Fc1: reference cell; Fc2: red diamond GST-HRASG12V-GTPγS (active form of HRAS target); Fc3: green
diamond GST-HRAS wild-type protein-GDP (inactive form of HRAS); Fc4: blue diamond recombinant GST only. e–g The RAS-binding compound Abd-1 was
shown by SPR (dose-response sensogrammes using 3.9, 7.81, 15.6, 31.3, 62.5, 125, 250, 500, 1 and 2mM compounds) to bind to mutant HRASG12V-GTPγS
(e), but not to HRASG12V-GTPγS-anti-RAS scFv complex (f) or HRAS-GDP (g). h–k Analogues of the initial hit were identified and shown to bind to
KRASG12V-GppNHp at 100 μM, run in triplicate
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interaction. We determined the effect of Abd-7 on the interaction
of KRASG12D and with PI3Kα and PI3Kγ, CRAF RAS-binding
domain (RBD) and RALGDS RAS-associating domain (RA)
compared with the low-affinity Abd-2 Fig. 4a). Abd-2 has no
effect on the BRET signal over a range of 5–20 μM, while Abd-7
reduces the BRET signal at 5, 10 and 20 μM for all of the RAS-
effector PPIs tested. A similar inhibitory effect of Abd-7, but not
Abd-2, was observed using five different glycine 12 mutations of
KRAS interacting with the full-length CRAF-GFP2 fusion
(Fig. 4b). Finally, we tested the efficacy of Abd-7, compared to
Abd-2, in the BRET assays using other RAS family members,
either NRASQ61H or HRASG12V, interacting with PI3Kα and
PI3Kγ, CRAF-RBD or full-length CRAF and RALGDS-RBD
(respectively, Fig. 4c, d). Abd-7 interferes with all mutant RAS
family member PPIs in this transfection assay. However, in this
type of assay, protein expression levels are difficult to control due
to the transient transfections, and the percentage of signal
reduction may vary between repetitions or between different
RAS-effector partners. The generation of stable cell lines could
reduce the differences on protein expression.
In order to assess the effect of our compounds on endogenous
RAS signalling, we analysed phosphorylation of AKT (down-
stream of RAS–PI3K signalling) and phosphorylation of ERK
(downstream of RAS–RAF signalling) using DLD-1 cells (a
colorectal line with KRASG13D mutation) and H358 cells (a
NSCLC with KRASG12C mutation). The cells were starved for 24
h, followed by incubation for 3 h with an increasing dose of Abd-
7 (range 2–20 μM) and stimulated EGF for 10 min to activate
KRAS signalling. Protein levels were determined by Western
analysis (Fig. 5a, b). While no change of endogenous AKT or ERK
1/2 was observed, inhibition of AKT phosphorylation (assessed
with anti-pAKT Ser473 antibody) was observed in both cell lines,
with response initiating between 2 and 5 μM, more than 50% at
10 μM and complete inhibition at 20 μM. No change was
observed in cyclophilin B (as a loading control on the Western
blots) (Fig. 5a, b). Similar dose responses were obtained for
inhibition of ERK1/2 phosphorylation by Abd-7 (assessed with
anti-pERK1/2 antibody) treatment of the cells. EGF stimulates
pERK production without affecting ERK1/2 levels, and diminu-
tion of pERK levels was found with a similar dose range of Abd-7
(Fig. 5a, b). We confirmed that Abd-7 is not directly binding to
kinase proteins themselves, using a binding assay with a panel of
kinase proteins, including RAF, MEK and PI3K (Supplementary
Table 3), endorsing the conclusion that control of phosphoryla-
tion depends on the direct binding of Abd-7 to RAS protein
rather than to other protein kinases. These cell assays show that
the lead compound Abd-7 is cell permeable and it exerts its
inhibitory function by interfering with PPI of RAS and effectors.
Independent evidence for cellular uptake was obtained using a
Caco-2 cell permeability assay (Papp A-B/B-A) 7.03/8.46
(10−6 cms−1).
We carried out cell viability studies using a monolayer culture
system with two human cancer cell lines with different RAS
family member mutations (DLD-1 KRASG13D and HT1080
NRASQ61K). A dose response was carried out with Abd-2, Abd-
4, 5, 6 and 7. Figure 5c (DLD-1) and 5d (HT1080) show cell
viability in the presence of 0–20 μM compound after 72 h
(Supplementary Fig. 7 shows viability at 24 and 48 h). The
lowest-affinity compounds, Abd-2 and Abd-4, show no effect on
cell viability even at the highest doses (these compounds also do
not show activity in the RAS biosensor BRET assay). Compounds
Abd-5 and Abd-6 have an effect on the viability (with Abd-5
showing a greater effect on DLD-1 viability); but even at 20 μM
Q61H/Abd-3
c
b
a
Q61H/Abd-2
G12D/Abd-3
Q61H/Abd-2
K56  
d
Fig. 2 Crystal analysis shows how compounds bind and VH competition
results. KRASQ61H or KRASG12D protein crystals were soaked with
compounds, and X-ray diffraction data were collected for determining the
binding modes of the compounds. a KRASQ61H-GppNHp soaked with
Abd-2. The expanded view of the binding region of this compound (right
hand panel) shows clear electron density (2mFo-DFc maps contoured at
1.0 r.m.s. green) attributed to the benzodioxane and furanyl amide parts
of the compound. b, c Crystal structures and electron densities for Abd-3
soaked into KRASQ61H-GppNHp or KRASG12D-GppNHp, respectively. The
chlorine atom in Abd-3 is depicted in green. The Abd-3–KRAS
interactions differ in two mutants, but the H-bond to a neighbouring
molecule in the crystal lattice for G12D means that the Q61H complex is
unencumbered by the crystal contacts (b). The switch I/II regions are
coloured in red and blue, respectively, are defined here as 30–38 (switch
I) and 60–76 (switch II). d Explanation for the competition of compound
Abd-2 binding to RAS by steric hindrance. The left-hand panel shows a
surface representation of mutant HRASG12V-GppNHp (light blue) and the
anti-RAS VH from the Fv depicted in orange. The left-hand panel is the
surface representation is the KRASQ61H-GppNHp structure soaked with
Abd-2, with anti-RAS VH superimposed on KRASQ61H-GppNHp. The
expanded right-hand representation shows the predicted steric hindrance
between VH and the compound, in particular VH CDR2 residue K56
(transparent, orange representation). Although the K56 side chain is
flexible, it is prevented from rotating away from the clash with Abd-2 by
steric hindrance with neighbouring regions of KRAS
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and after 72 h, there are surviving cells following incubation with
either compound. The most potent compound is Abd-7 (whose
in vitro Kd is 51 nM) with an IC50 of 8 μM in DLD-1 and 10 μM
in HT1080 at 72 h (similar values for the IC50 were found after
48 h (Supplementary Fig. 7f). These results showed that the ability
of our chemical series to affect cancer cell viability relates to their
binding properties, and that Abd-7 is the most cell-potent
inhibitor affecting the viability of cancer cell lines in a single digit
to low micromolar range.
Discussion
Intracellular antibodies are highly specific research tools for
target validation3 nonetheless scFv, single domain intracellular
antibodies (iDAbs)13 and single camelid VH domains (nano-
bodies)43,44 have not been implemented as therapeutic agents. An
alternative use of intracellular antibodies is to select small
molecules that bind to the same region of target antigens and can
thence potentially be developed into drugs5,45,46. Our work
describes the use of an intracellular antibody fragment that
competes RAS-effector PPI3, to select a compound in vitro from a
chemical fragment library that binds to RAS family proteins at
the cognate site. The method depends on a high-affinity inter-
action between the intracellular antibody fragments and to allow
sustained interaction during the cSPR. This cannot be achieved
using natural partner proteins (e.g. RAS-effectors) as these have
low binding affinity with high Koff. We thus show in this work
that a single domain intracellular antibody fragment, which was
derived against mutant HRAS and used for target validation of
RAS-effector PPIs, could be used in a competition assay to select
RAS-binding compounds from a fragment library. This created a
chemical basis for development, by medicinal chemistry and SAR,
of a compound series with improved properties, guided by high-
resolution X-ray crystallography. We generated a soluble lead
compound with low nM Kd, that is both cell permeable, was able
to block RAS PPIs in human cancer cells, and to affect the via-
bility of the cells. Although, various RAS inhibitors have been
described in literature,24–32,47,48, in this paper we describe an
approach for the development of RAS-effector inhibitors by com-
bining different elements i.e. (i) the hit identification via a method
of intracellular antibody fragment competition; (ii) structure-based
design via crystal structures (KRASQ61HGPPNHP) and NMR
(waterLOGSY and CPMG); (iii) identification of clear structure-
activity relationship (SAR) for the development of potent com-
pounds against KRAS and (iv) the proof of concept in mechanistic
and phenotypic cell assays.
Our medicinal chemistry, guided by high-resolution crystal-
lography allowed the improvement of our initial Abd-2, that
binds in a previously observed pocket, through to the nM-binding
compound Abd-7 (Fig. 3). X-ray crystallography using crystal
soaking showed how the initial hits bind to KRAS and how the
antibody fragment VH interferes with this binding (Fig. 2d,
Fig. 6) Our guided approach has led to the identification of a
novel series of compounds that interfere with the oncogenic
function of RAS and whose binding features are confirmed.
Different groups have described compounds binding to this same
pocket, however, there has been no structure-based design of
direct RAS-effector inhibitors done in that region. The difficulties
of identifying a suitable crystal packing conditions of mutant
KRAS to soak compounds contributes to the difficulties of gen-
erating SAR and, consequentially, of generating highly potent
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Fig. 3 RAS-binding series development from antibody-derived initial hit. Representative examples of KRAS-binding compounds Abd-4 to Abd-7 guided by
structural biology information. a Chemical structures of the chemical series with numbering on different rings. b Crystal structures with the mode of
binding of each compound to KRASQ61H-GppNHp (shown in grey) in the pocket close to the switch regions I (red) and II (blue). Each new analogue has
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compounds binding to pocket. We have solved this by exploiting
and optimizing known crystallisation conditions for KRASQ61H
(PDB code 3GFT).
The initial fragment compound (Abd-2) was improved by
introducing pyridine functionalities to position 8 of the benzene
ring from the benzodioxane moiety, enhancing the Kd from μM
to nM with increased ligand efficiency values from 0.26 of Abd-2
to 0.34 of Abd-7 (Supplementary Fig. 6). An expansion of the
interactions is observed when Abd-4 was evolved to Abd-7
(Supplementary Fig. 8). One of our objectives was to show that
intracellular antibody fragments could be used for chemical
compound hit identification and to find compounds that emulate
the inhibition of PPI shown by the antibody3 in cells. We used a
BRET2-based assay to evaluate the intracellular inhibition of RAS
PPI by Abd-7, compared to the low affinity compound Abd-2 and
showed that Abd-7 impairs the PPI of various mutant KRAS
proteins with PI3K, CRAF and RALGDS as well as NRASQ61H
and HRASG12V but Abd-2 does not (Fig. 4). RAS-dependent
signalling occurs via several kinase molecules, including phos-
phorylation of AKT (the RAS-PI3K pathway) and ERK (the RAS-
RAF pathway). The Abd-7 compound inhibits phosphorylation of
both downstream biomarkers (Fig. 4a, b) in colorectal cancer
(DLD-1, KRASG13D) and non-small cell lung cancer (H538,
KRASG12C) human cell lines in a dose dependent way, with
reduction of AKT phosphorylation starting at 2 μM. These effects
occur within 2 h of Abd-7 treatment while there is no effect on
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Fig. 4 Abd-7 disrupting RAS-effector interactions. HEK293T cells were transfected with different BRET-based RAS biosensor expression vectors to
evaluate the inhibition of RAS PPI in cells by compound Abd-7. Transfection vector encoded full-length RAS was fused to the donor molecule RLuc8 and the
effectors fused to the acceptor molecule GFP2. a Effect of Abd-2 and Abd-7 on KRASG12D interaction with PI3Kα, PI3Kγ, CRAF or RALGDS. The BRET signal
is plotted as a % of control cells treated with DMSO only and dose response to 5, 10 and 20 μM of each compound. b Effect of Abd-2 and Abd-7 on the
BRET signal from interaction of KRASG12 mutants (Rluc8-KRASG12) and full-length CRAF (GFP2-CRAF FL). c, d Effect of Abd-2 and Abd-7 on the interaction
of NRASQ61H (c) and HRASG12V (d) with various RAS effectors domain and with full-length CRAF. The BRET ratio corresponds to the light emitted by the
GFP2 acceptor constructs (515 nm ± 30) upon addition of Coelenterazine 400a divided by the light emitted by the RLuc8 donor constructs (410 nm ± 80).
The normalized BRET ratio is the BRET ratio normalized to the DMSO negative and calculated as follows: (BRETcompound/BRETDMSO) x 100, where
BRETcompound corresponds to the BRET ratio for the compound-treated cells, BRETDMSO to the DMSO-treated cells. Each experiment was repeated at least
three times. Statistical analyses were performed using a one-way ANOVA followed by Dunnett’s post-tests (*P < 0.05, **P < 0.01, ***P < 0.001, ****P <
0.0001). Where error bars are presented, they correspond to mean values ± SD of biological repeats (a–c)
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the overall AKT or ERK protein levels. Abd-7 is, therefore, an
inhibitor of RAS-effector PPI. The mechanism by which Abd-7
interferes with RAS-effector PPI is indicated from the crystal
structure data. The binding of the CRAF, RALGDS and PI3K
effectors to RAS is similar and very close to the binding site of
Abd-7. In Fig. 6, RAS with bound Abd-7 is superimposed to
structures of RAS-effector complexes showing that the terminal
tertiary ammonium group, and adjacent phenyl ring, of Abd-7
overlaps with the bound effector structures. The competition
effect of Abd-7 on the binding of the effectors with RAS in cells,
can therefore be interpreted as steric hindrance of the lower
affinity effectors by the higher affinity Abd-7. However, despite
observing similar steric disruption of Abd-7 (Fig. 6), there are
differences observed in the reduction of phosphorylation of
pAKT and pERK in cells. These differences could be associated
with the variations in affinity of the effectors towards KRAS. For
example, Pi3K has an estimated affinity of 3.2 μM, while RAF has
an affinity of 0.08 μM6.
The susceptibility of cancer cells to the compounds in our
chemical series was compared between the two human cell lines
with different RAS family mutations (DLD-1 with mutant
KRASG13D and HT1080 with mutant NRASQ61K) using standard
viability assays. The effect of the compounds on cell survival
correlated with the potency of the compounds in binding using
in vitro NMR and crystallography. The early compound (Abd-2),
that was the direct descendent of the initial hit obtained using the
cSPR, had not effect on either cell type, up to 72 h and the
maximum concentration used (20 μM) (Fig. 5c, d). Compound
Abd-7 displayed the highest IC50 (approximately 8 μM in DLD-1
and 10 μM in HT1080 at 48 h, (Supplementary Fig. 7), had the
lowest Kd (51 nM) and shows consistent inhibitory effects in the
cell-based BRET assay and the biomarker assay. The observed
discrepancy between affinity (in vitro Kd) and efficacy (IC50 in
cells) is a known challenge that can be addressed through
chemistry. A comparison between Abd-6 and Abd-7 affinity Kds
and cell IC50 demonstrates that by chemical modifications, one
can increase cell potency while maintaining a similar-affinity Kd.
Further increase of potency could be achieved by new analogue
synthesis based on structural biology information as demon-
strated in our work. In addition, it is also known that dis-
crepancies between in vitro and in cellulo potencies can be
associated with targets, such as RAS, with high conformational
variability and allosteric modulators49,50. Furthermore, the dis-
crepancy could be exacerbated by permeability, efflux and free
drug vs total drug availability, target location and biochemical
state.
In summary, our results show that intracellular antibody-based
selection of small compound ligands for specific proteins is
practical and should provide a means to make compounds for
disrupting abnormal protein function in any disease. Antibody
fragments can be sequentially used for target validation and PPI
epitope determination prior to drug development. Our approach
allowed us to develop a series of compounds that bind to KRAS
with high affinity, interfere with RAS PPI and inhibit RAS-
dependent signalling in human tumour cells. This realizes the
potential of allowing the replacement of antibody fragments
(macrodrugs) with small molecule (conventional) potential drugs.
Methods
Fragment library. A fragment library comprising 656 compounds, triaged for
potential drug-like precursors, was used with molecular weight range from 94 to
341 Da, composed of chemical fragments that followed the “rule of three”
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(molecular weight ≤ 300 Da, clogP ≤ 3, the number of hydrogen bond donors and
acceptors each <3 and the number of rotatable bonds <3) and small molecules
above 300 Da. Each compound was dissolved at 200 mM in 100% DMSO and 41
compounds were removed from the library because of insolubility in DMSO i.e.
from the library, 615 useful compounds could be screened at the concentrations
used. The library was replica plated (20 mM concentration) and stored at −80 °C.
The initial hit compound (Maybridge) was N-(2-quinolinyl)-2-furamide
(C14H10N2O2), product code HTS05481, MW:238.2456, clogP 2.33, Rotatable
bonds: 2, H-bonds donor: 1, H-bonds acceptor 4.
Recombinant protein expression for SPR and NMR. Recombinant GST fusion
RAS proteins were prepared by expression of HRAS (1-166) HRASG12V or
KRASG12V cDNA cloned into the pGEX-2T vector in-frame with an N-terminal
glutathione-s-transferase. pGEX-HRAS(wt) and pGEX-HRASG12V plasmids were
transformed into E. coli C41(DE3). Bacterial cells were cultured at 37 °C to an
OD600 of 0.6 and induced with IPTG (isopropyl 1-thio-beta-D-galactopyranoside,
final concentration 0.1 mM) at 30 °C for 5 h. The bacteria cultures were harvested
by centrifugation and the cell pellets re-suspended in 140 mM NaCl, 2.7 mM KCl,
10 mM NaH2PO4, 1.8 mM KH2PO4, 1 mM EDTA, 2 mM MgCl2 pH 7.4. The
proteins were extracted by cell disruption (Constant Systems Ltd., UK) at 25,000
psi at 4 °C. The GST-fusion proteins were purified by glutathione-sepharose col-
umn chromatography (GE Healthcare) and eluted with 50 mM Tris-HCl pH 8.0,
10 mM reduced glutathione, 1 mM DTT, 2 mM MgCl2. The eluted proteins were
dialysed against 50 mM Tris-HCl pH 8.0, 1 mM DTT, 2 mM MgCl2 and con-
centrated to 10 mg/ml using a Biomax-30 ULTRAFREE-15 centrifugal filter device
(Millipore). To exchange endogenous guanidine nucleotide bound to RAS to GDP
or GTP analogue, purified GST-RAS proteins were loaded with GTPγS, GppNHp
or GDP (Sigma). Nucleotide exchange for SPR and NMR samples was done by
preparing a final solution of 1 ml containing 400 ul of KRAS protein (final 0.63
mM), 94 μl of GPPNHP (16 times excess), 100 μl of alkaline phosphatase buffer
[0.5 mM Tris Ph 8.5, 10 mM EDTA, 2 M (NH4)2SO4], 100 μl of alkaline phos-
phatase (30 units/ml) and 307 μl of H2O51. KRAS protein samples were con-
centrated using Vivapore 10/20 ml concentrator (7.5 kDa molecular weight cut-off;
Sartorius Vivapore). The proteins were further purified by gel filtration on a
HiLoad Superdex 75 10/300 GL column (GE Healthcare, Uppsala, Sweden) in a
buffer containing 10 mM PBS pH 7.4, 5 mM MgCl2 at a flow rate of 0.5 ml/min.
Fractions corresponding to the protein were pooled and concentrated. Protein
concentration was determined by extinction coefficient at 280 nm by using Prot-
Param tool. Protein purity was analysed by SDS-PAGE stained with Instant Blue
(Expedeon). For purification of anti-RAS scFv or VH, the plasmids pRK-HISTEV-
scFv or pRK-HISTEV-VH were prepared by sub-cloning scFv or VH fragment into
the pRK-HISTEV vector giving in-frame fusion with a 6x histidine tag and a TEV
protease site. The plasmids were transformed into C41 (DE3), cultured at 37 °C to
an OD600 of 0.6 and induced with IPTG (final 0.5 mM) at 16 °C for 12 hours. scFv
protein was extracted from bacteria pellets using sonication and a French press
with the extraction buffer (25 mM Na phosphate, pH 7.4, 500 mM NaCl, 20 mM
imidazole) and purified using His-Trap Ni-affinity columns (GE Healthcare)
employing gradient elution (20–300 mM imidazole). The his-tag peptide was
removed from the purified protein by treatment with TEV protease and dialysed in
20 mM Tris-HCl pH8.0, 300 mM NaCl, 20 mM imidazole at 4 °C overnight.
The scFv was purified again by passing through a Ni-NTA agarose column
(Qiagen) and by gel filtration on a HiLoad Superdex-75 HR column (GE
Healthcare) in 20 mM Tris-HCl pH8.0, 250 mM NaCl and concentrated to 10 mg/
ml for storage.
Recombinant protein expression for crystallography. KRAS169Q61H and
KRAS188G12D cDNAs were cloned into the pRK-172 vector using NdeI and BamHI
restriction sites, in-frame with an N-terminal 6x his-tag and the TEV protease
recognition site. Plasmids containing pRK-172-KRAS169Q61H and KRAS188G12D
sequences were transformed individually into B834(DE3)pLysS cells, which were
grown in 25 ml LB medium with 50 μg/ml carbenicillin and 34 μg/ml chlor-
amphenicol for 16 hours at 37 °C, before adding to 1 l LB medium containing the
same antibiotics. Protein expression was induced when cells reached an OD600
of 0.6 by addition of IPTG to a final concentration of 0.5 mM, followed by over-
night incubation at 16 °C. Bacteria were harvested by centrifugation (5180 g, 30
min, 4 °C), resuspended in 60 ml of lysis buffer 50 mM Tris-HCl, pH 7.5, 500 mM
NaCl, 5 mM MgCl2 and 10 mM imidazole also containing one EDTA-free protease
inhibitor cocktail table (Roche Diagnostics, Mannheim, Germany). Cells were lysed
by sonication using five 30 s pulses at level of 16 and insoluble debris removed by
centrifugation (75,600 g, 20 min, and 4 °C). The supernatant was applied to a
column of nickel agarose beads (Invitrogen) by gravity, the beads were washed
twice with lysis buffer containing 50 mM imidazole and bound proteins were eluted
in 50 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5 mM MgCl2, 300 mM imidazole.
HIS-tagged TEV protease (1.4 mg/ml) was added to the KRAS188G12D at a ratio
of 1:100 to the eluate and the sample dialysed against 50 mM Tris-HCl, pH 7.5,
500 mM NaCl, 5 mM MgCl2, overnight at 4 °C. The TEV protease and cleaved
HIS-tag fragment were removed by re-application of the digestion to nickel agarose
beads (Invitrogen). Samples containing KRAS protein were concentrated using
Vivapore 10/20 ml concentrator (7.5 kDa molecular weight cut-off; Sartorius
Vivapore). Endogenous guanidine nucleotide bound to RAS was exchanged to a
GTP analogue and purified KRAS proteins were loaded with GppNHp (Sigma)
following the same protocol described for the SPR and NMR experiments. The
proteins were further purified by gel filtration using a Superdex 75 Increase 10/300
GL column (GE Healthcare, Uppsala, Sweden). KRAS169Q61H was equilibrated with
20 mM HEPES pH 8.0, 150 mM NaCl, 5 mMMgCl2 and 1 mM DTT and applied to
the column at a flow rate of 0.5 ml/min. For KRAS188G12D buffer used to
equilibrate the column and elute the protein was 25 mM TrisCl, pH 8.0, 100 mM
NaCl, 5 mM MgCl2 and 1 mM TCEP. Fractions corresponding to KRAS were
pooled and concentrated to 45–75 mg/ml for crystallisation trials. Protein
concentration was determined from the extinction coefficient at 280 nm using
ProtParam tool. Protein purity was confirmed by SDS-PAGE stained with Instant
Blue (Expedeon).
HRAS small-molecule screening and competitive SPR. A BIAcore T100 (GE
Healthcare) was used to screen the fragment library for RAS binders. A polyclonal
goat anti-GST antibody (GE Healthcare) was immobilized on a CM5 sensor
chip (GE Healthcare) by the amine coupling method. To immobilize the antibody
on CM5 chip, the chip was first activated by injecting 100 µl mixture of 0.2 M EDC
(N-ethyl-N-(dimethylaminopropyl) carbodiimide hydrochloride) and 0.05 M NHS
(N-hydroxysuccinimide) at 10 µl/min flow rate. Furthermore, 100 µg/ml anti-GST
antibody in 10 mM sodium acetate, pH 5.0 was injected at 5 µl/min for 900 s and
immobilized until 20,000 ~ 25,000 RU. After immobilization the chip was
immediately inactivated by injecting 1M ethanolamine, pH 8.5 at 10 µl/min for
600 s. The chip was kept running in the HBS buffer (GE Healthcare) comprising
10 mM HEPES, pH 8.0, 150 mM NaCl. Of all, 5 µg/ml recombinant GST, GST-
a
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Fig. 6 Superimposed structures of KRAS169Q61H-Abd-7 and RAS-effectors
(RAF, Pi3K and RALGDS). The potential interactions that could prevent
Abd-7 and a RAS effector binding simultaneously to the same KRAS
molecule have been modelled by overlaying the structure of the
KRAS169Q61H-Abd-7 complex onto published structures. In each case,
simultaneous binding of KRAS to Abd-7 and the effector is sterically
forbidden. a, b Overlay with HRAS-CRAF RBD (PDB 4G3X). Abd-7 would
overlap with residues 62-67 of CRAF. c, d Overlay with HRAS-RALGDS
RBD (PDB 1LFD). Abd-7 would overlap with residues 29-31 of RALGDS. e, f
Overlay with HRAS-PI3Kγ RBD (PDB 1HE8). Abd-7 would overlap with
residues 227-229 for PI3K
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HRASG12V-GTPγS or GST-HRASG12V-GDP proteins were injected into flow cell
Fc4, Fc2 and Fc3, respectively for trapping through the immobilized anti-GST
antibody. The GST-HRASG12V-GTPγS, GST-KRASG12V-GppNHpp, or GST-
HRASG12V-GDP proteins were injected at 5 µl/min for 900 s and usually reached
approximately 2000–2500 RU. The GST was injected at same flow rate until about
1200–1350 RU which is 0.54 times less than the GST-HRASG12V-GTPγS or GST-
HRAS-GDP capture amounts, taking into consideration relative molecular weights
(GST, 26KDa, GST-RAS, 48KDa, respectively). Before fragment library screening,
the running buffer was replaced by 20 mM Tris, pH 8, 150 mM NaCl, 5 mM
MgCl2, 5% DMSO. DMSO solvent correction curves were generated by injecting
the running buffers with serial concentrations of DMSO ranging from 4.5 to 6%.
For fragment screening, each compound was diluted at 200 µM or 1 mM, 5%
DMSO in 20 mM Tris, pH 8, 150 mM NaCl, 5 mM MgCl2 buffer in a poly-
propylene 96 well plate. The individual compounds were injected at 30 µl for 60 s at
30 µl/min flow rate over flow cells Fc1, Fc2, Fc3 and Fc4. The captured GST and
GST-RAS were removed from the chip by rinsing with 40 µl 10 mM glycine-HCl,
pH 2.1 at 20 µl/min flow rate after every 48 compounds sequential injection. The
chip was regenerated by injecting new GST and GST-RAS proteins as described
above.
For competitive SPR (cSPR) assays between anti-RAS scFv and candidate
fragment binder, after immobilizing anti-GST polyclonal antibody was
immobilized on CM5 sensor chip as described above, then 5 µg/ml GST-HRAS-
GTPγS protein was injected at 5 µl/min for 900 s to flow cells Fc2 and 4 and
5 µg/ml GST-HRAS-GDP to Fc3. Following GST-HRAS capture on the flow cells,
5 µg/ml anti-RAS scFv Y6-204 was injected at 5 µl/min for 900 s only to Fc4 until
reaching an additional 1500–1800 RU, which is theoretically when all GST-HRAS-
GTPγS should be bound to anti-RAS scFv with 1:1 interaction stoichiometry. After
completing anti-RAS scFv injection, the sensograms were confirmed to be stable
(i.e. anti-RAS scFv was not dissociated from GST-HRAS-GTPγS on Fc4). The
candidate compounds were diluted at 15 µM to 2 mM serial concentrations in
running buffer with final 5% DMSO, and a volume of 30 µl was injected for 60 s at
a rate of 30 µl/min over all four flow cells of the CM5 chip.
The corresponding kinetic rate constants, Kon and Koff, were determined using
steady-state analysis of the compounds’ binding affinities, assuming 1:1 ligand-
protein stoichiometry. The BIAcore evaluation 2.1 software provided by the
manufacture was used to analyse the data.
Calculations for the number of response units are required for a 1:1 ratio of
compound/protein interaction are shown below.
Protein immobilization: 2500 RU; average fragment 250 approx. Da in size.
Rmax= (MWA/MWL) x RL x SM
MWA is the molecular weight of the analyte in Da
MWL is the molecular weight of the ligand in Da
RL is the immobilization level in RU
SM is the molar stoichiometry (assume 1:1)
Rmax= 250/47,500 × 2500 × 1
Rmax= 13 RU
WaterLOGSY NMR. The waterLOGSY NMR method35 was used to measure RAS
ligand interaction52. WaterLOGSY experiments were conducted at a 1H frequency
of 600MHz using a Bruker Avance spectrometer equipped with a BBI probe. All
experiments were conducted at 298 K, 3 mm diameter NMR tubes with a sample
final volume of 200 µl was used in all experiments. Solutions were buffered using an
H2O 10 mM PBS, 5 mM MgCl2 buffer corrected to pH 7.4. The sample preparation
is exemplified as follows, the compound (10 µl of a 10 nM solution in DMSO-d6)
was added to an eppendorf before sequential addition of the H2O PBS buffer
(163.6 µl), D2O (20 µl), and protein (6.4 µl, 311.8 µM). The resulting solution was
spun to ensure full mixing and transferred to a 3 mm NMR tube before running the
experiment. For a competition experiment using Y6-scFv or VH, the preparation
was carried out in a similar manner; the compound (10 µl of a 10 mM solution in
DMSO-d6) was added to an eppendorf before sequential addition of the H2O PBS
buffer (146.4 µl), D2O (20 µl), protein (6.4 µl, 311.8 µM) and Y6-ScFv (17.2 µl,
116.6 µM) with a ratio of 5.5:1:1. The resulting solution was spun and transferred to
a 3 mm NMR tube before the run. Negative controls (compound alone, without the
protein) were prepared in a similar manner, in order to obtain an end volume of
200 μl.
1H CPMG NMR. Typical experimental parameters for Carr–Purcell-Meiboom-Gill
(CPMG) NMR spectroscopy were the following: total echo time, 40 ms; relaxation
delay, 2 s; and number of transients, 26453. The PROJECT-CPMG sequence (90°x-
[Ƭ-180°y-Ƭ- 90°y-Ƭ-180°y-Ƭ]n-acq) was applied. Water suppression was achieved
by pre-saturation. Prior to Fourier transformation, the data were multiplied with an
exponential function with 3-Hz line broadening. The CPMG experiments were
conducted at a 1H frequency of 700MHz using a Bruker Avance with 5 mm inverse
TCI 1 H/13 C/15 N cryo-probe. All experiments were conducted at 298 K and
lapsed 128 scans. Furthermore, 3 mm diameter NMR tubes with a sample volume
of 200 µl were used in all experiments. Solutions were buffered using a D2O PBS
buffer corrected to pH 7.4. The sample preparation is exemplified as follow: with
5 µM of protein (PBS pH 7.4, 5 mM MgCl2), the compound (1.1 µl of a 10 mM
(55 uM) solution in DMSO-d6) was added to an eppendorf before sequential
addition of the D2O 10 mM PBS, 5 mM MgCl2 buffer adjusted to pH 7.4 (194.0 µl)
and protein (4.9 µl, 205 µM, the protein is in an H2O-based buffer for stability
reason). The resulting solution was vortexed to be fully mixed and transferred to a
3 mm NMR tube before the run. Negative controls (compound alone, without the
protein) were prepared in a similar manner, in order to obtain an end volume of
200 µl. CPMG protein titration experiments were carried out at a fixed compound
concentration and a variable protein concentration. It was estimated that 55 μM
solution of the compound was optimum for a good CPMG; protein was titrate
increasingly from 0 µM until the signal of the compound was undetected in the
proton NMR. The integrations of the protons acquired were compared to the
reference (compound alone, 0 µM of protein) in order to obtain a percentage of
decrease for each concentration of protein. Three different proton signals were
used and a mean was calculated for each run. Each protein concentration was run
in triplicate and a mean was calculated for each concentration. Where error bars
are presented, they correspond to mean values ± SD of experimental repeats.
Concentration and percentage of decrease were plotted and Kd fitting was run on
the generated curve using Origin® with the following function: A*(1/(2*C))*((B+
x+ C)-sqrt(((B+ x+ C)^2)-(4*x*C))) where A is the maximum % of inhibition
(i.e. 100), B is the Kd and C is the concentration of the compound which should
not be fixed in the Origin® Equation due to potential variations in compound
solubility.
General experimental notes and instrument settings. All solvents and reagents
were used as supplied (analytical or HPLC grade) without prior purification. Water
was purified by an Elix® UV-10 system. Brine refers to a sat. aq. solution of sodium
chloride. In vacuo refers to the use of a rotary evaporator attached to a diaphragm
pump. Pet. ether refers to the fraction of petroleum spirit boiling between 30 and
40 °C, unless otherwise stated. Thin layer chromatography was performed on
aluminium plates coated with 60 F254 silica. Plates were visualized using UV light
(254 nm) or 1% aq. KMnO4. Flash column chromatography was performed on
Kieselgel 60 M silica in a glass column. NMR spectra were recorded on Bruker
Avance spectrometers (AVII400, AVIII 400, AVIIIHD 600 or AVIII 700) in the
deuterated solvent stated. The field was locked by external referencing to the
relevant deuteron resonance. Chemical shifts (δ) are reported in parts per million
(ppm) referenced to the solvent peak. 1H spectra reported to two decimal
places, and 13C spectra reported to one decimal place, and coupling constants (J)
are quoted in Hz (reported to one decimal place). The multiplicity of each signal
is indicated by: s (singlet); br. s (broad singlet); d (doublet); t (triplet); q (quartet);
dd (doublet of doublets); td (triplet of doublets); qt (quartet of triplets); or m
(multiplet). Low-resolution mass spectra were recorded on an Agilent 6120 spec-
trometer from solutions of MeOH. Accurate mass measurements were run on
either a Bruker MicroTOF internally calibrated with polyalanine, or a Micromass
GCT instrument fitted with a Scientific Glass Instruments BPX5 column (15 m ×
0.25 mm) using amyl acetate as a lock mass, by the mass spectrometry department
of the Chemistry Research Laboratory, University of Oxford, UK.; m/z values are
reported in Daltons.
Analytical methods. Analysis of products and intermediates was carried out using
reverse phase analytical HPLC-MS as well as normal phase analytical LCMS-MS.
HPLC analytical methods: AnalpH2_MeOH_4min: Phenomenex Luna C18
(2) 3 μm, 50 × 4.6 mm; A=water+ 0.1% formic acid; B=MeOH+ 0.1% formic
acid; 45 °C; %B: 0.0 min 5%, 1.0 min 37.5%, 3.0 min 95%, 3.5 min 95%, 3.51 min
5%, 4.0 min 5%; 2.25 ml/min. AnalpH2_MeOH_QC_V1: Phenomenex Gemini NX
C18 5 μm, 150 × 4.6 mm; A=water+ 0.1% formic acid; B=MeOH+ 0.1% formic
acid; 40°C; %B: 0.0 min 5%, 0.5 min, 5%, 7.5 min 95%, 10.0 min 95%, 10.1 min 5%,
13.0 min 5%; 1.5 ml/min. LCMS Analytical Methods: LCMS Agilent_Gen Method
A [100–1000] 6 MIN: Phenomenex Gemini NX C18 5 μm, 150 × 4.6 mm; A=
water+ pH 9 (Ammonium Bicarbonate 10 mM); B=MeOH; 40°C; %B: 0.0 min
5%, 0.50 min 5%, 7.5 min 95%, 10.0 min 95%, 10.1 min 5%, 13.0 min 5%; 1.5 ml/
min.
1H and 13C NMR spectra of Abd-2 to Abd-7 and LCMS data for Abd-2, Abd-
2a, Abd-2b are shown in Supplementary Figs. 9–16. Chemical synthesis protocols
are available in Supplementary notes 1–7.
X-ray crystallography. For X-ray diffraction experiments, KRASQ61H-GppNHp
crystals were grown at 4 °C from 1.5 ± 1.5 µl vapour diffusion drops containing
75 mg/ml KRASQ61H, 8–15% w/v Polyethylene Glycol 3350 and 0.2 M lithium
citrate pH 5.5 giving crystal form I. For KRASG12D–GppNHp crystals, drops were
prepared by mixing 1.5 μl of protein at 45 mg/ml with 1.5 μl of reservoir consisting
of 0.1 M TrisCl pH 8.0, 0.2 M NaOAc and 32% PEG 4000 in 24-well Cryschem
sitting-drop plates giving crystal form II. For data collection, crystals were cryo-
protected by addition of 20% glycerol and flash-cooled in liquid nitrogen. For
crystal soaking experiments, compounds were added individually (25–50 mM or
saturated solution of compound with a final DMSO concentration of 6–12% v/v) to
the crystallisation buffer. Crystals were then transferred to solution containing
compound for a minimum of 5 min. Soaked crystals were cryo-protected with 20%
glycerol and flash-cooled in liquid nitrogen for data collection. In each case, X-ray
diffraction data were collected at the Diamond Light Source (DLS, Oxfordshire).
The structure of KRASQ61H GppNHp–Abd2 to Abd-7 and KRASG12D GppNHp-
compound Abd-3 were solved by molecular replacement using Protein Data Bank
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(PDB) codes 3GFT and 4DSU, respectively, with the programme Phaser54,55.
Structures were refined using REFMAC in the CCP4 suite56 and manually cor-
rected using Coot57. Crystal form I (KRASQ61H) has six KRAS molecules in the
asymmetric unit, assembled as a hexamer. Electron density maps averaged with six-
fold non-crystallographic symmetry (NCS) were used to improve the definition of
the bound compounds. Local ncs averaging within REFMAC was used throughout
refinement and the final models were validated using PROCHECK molPROBIT
and Phenix software packages58,59. Figures were created using PyMOL60. Data
collection and refinement statistics are summarized in Supplementary Tables 1 and 2.
The PBD codes for the structures presented in this paper are:
KRAS169Q61H GPPNHP-Abd-2 PDB ID: 5OCO
KRAS169Q61H GPPNHP-Abd-3 PDB ID: 5OCT
KRAS188G12D GPPNHP-Abd-3 PDB ID: 5OCG
KRAS169Q61H GPPNHP-Abd-4 PDB ID: 6FA1
KRAS169Q61H GPPNHP-Abd-5 PDB ID: 6FA2
KRAS169Q61H GPPNHP-Abd-6 PDB ID: 6FA3
KRAS169Q61H GPPNHP-Abd-7 PDB ID: 6FA4
Kinase panel binding assay. Experiments were performed by Eurofins Pharma
Discovery Services. The KinaseProfiler™ assay protocol guide can be downloaded
from their website: www.eurofins.com/discoveryservices. The guide contains
information on the buffer conditions, substrate and reference inhibitor blank used
for each kinase.
Tissue culture assays. HEK293T human embryonic kidney cells were grown in
DMEM medium (Life Technologies) supplemented with 10% FBS (Sigma) and 1%
Penicillin/Streptomycin (Life Technologies). Cells were grown at 37 °C with 5%
CO2. Cells were obtained for the American Tissue Culture Collection except
HEK293T that was obtained locally.
BRET2 cell assay. The BRET assay was carried out as described elsewhere42. A
total of 650,000 HEK293T were seeded in each well of a six well plate. Approxi-
mately, 24 h later, cells were transfected with an appropriated BRET-based RAS
biosensor (i.e. RAS-effector) using Lipofectamine 2000 transfection reagent
(Thermo-Fisher). Cells were detached 24 h later and washed with PBS and seeded
in a white 96 well plate (clear bottom, PerkinElmer, cat#6005181) in OptiMEM no
phenol red medium (Life Technologies) complemented with 4% FBS. Cells were
left for 4 h at 37 °C before adding compounds. Stock compounds were held at
10 mM in 100% DMSO and diluted in OptiMEM no red phenol+ 4% FBS to reach
10X the final concentration (2% DMSO for each concentration). The final con-
centrations in the cells were 0, 5, 10 and 20 μM (therefore the intermediate 10X
concentrations were 0, 50, 100 and 200 μM. Furthermore, 10 μl of 10X compounds
were added in each well of the 96 well plate to 0, 5, 10 and 20 μM final con-
centrations (with final 0.2% DMSO each). Quadruplicates were performed for each
point. Cells were left for an additional 20 h at 37 °C before the BRET2 signal
reading directly after addition of Coelenterazine 400a substrate (10 μM final) to
cells (Cayman Chemicals, cat#16157). BRET2 reading was carried out on an
Envision instrument (2103 Multilabel Reader, PerkinElmer) with the BRET2 Dual
Emission optical module (515 nm ± 30 and 410 nm ± 80; PerkinElmer).
Biomarker phosphorylation assay. A total of 450,000 DLD1 or 640,000 H358
cells were seeded per well of a six well plate. Approximately, 20 h later, the medium
was removed, the cells washed twice with PBS and DMEM without FBS was added
and left for 24 h. The medium was removed and 2 ml of DMEM no FBS was added
with the appropriate concentration of compound (DMSO, 2, 5, 10 or 20 μM) for
3 h. Cells were stimulated with EGF (50 ng/ml) for 10 min, washed once with PBS
and directly lysed in SDS-Tris buffer (1% SDS, 10 mM Tris-HCl pH 7.4) supple-
mented with protease inhibitors (Sigma) and phosphatase inhibitors (Thermo-
Fisher). Cell lysates were sonicated with a Branson Sonifier and the protein con-
centrations determined by using the Pierce BCA protein assay kit (Thermo-Fisher).
Furthermore, 10 μg of protein were resolved on 10 or 12.5% SDS-PAGE and
subsequently transferred onto a PVDF membrane (GE). The membrane was
blocked (with 10% non-fat milk (Sigma) or 10% BSA (Sigma) in TBS-0.1%
Tween20) and incubated overnight with primary antibody at 4 °C. Primary anti-
bodies include anti-phospho-p44/22 MAPK (ERK1/2) (1/4000, CST, Cat#9101S),
anti-p44/42 MAPK (total ERK1/2) (1/1000, CST, Cat#9102S), anti-phospho-AKT
S473 (1/1000, CST, Cat#4058S), anti-AKT (1/1000, CST, Cat#9272S), anti-
cyclophilin B (1/1000, Abcam, Cat#178397). After washing, the membrane was
incubated with an anti-rabbit IgG HRP-linked (1/3000, CST, Cat#7074S) secondary
antibody for 1 h at room temperature. The membrane was washed with TBS-0.1%
Tween and developed using Pierce ECL Western Blotting Substrate (Thermo-
Fisher) and CL-XPosure films (Thermo-Fisher). Uncropped Western blots are
shown in Supplementary Fig. 17.
Cell viability assays. Cancer cell lines were in seeded in ViewPlates-96 micro-
plates (PerkinElmer). DLD-1 cells were plated at 10,000 cells per well and HT1080
cells at 7500 cells per well and cultured in DMEM, high glucose, GlutaMAX media
containing 10% FBS at 37 °C in 5% CO2 atmosphere. Cells were cultured overnight
and the compounds (dissolved in DMSO and diluted to 0.2% DMSO) were added
to the cells at concentrations ranging from 0 to 20 μM. The cells were incubated
under standard culture conditions for either 24, 48 or 72 h. Cell viability was as
quantitated using the CellTiterGlo Luminescent Cell Viability Assay (Promega)
according to the manufacturer’s instructions to measure ATP generated by
metabolically active cells. Luminescent signals were measured using an Envision
2103 Multilabel Microplate Reader (PerkinElmer). The luminescence signals
obtained from the compound-treated cells were normalized against the signal for
DMSO-only treated cells. The IC50 values, calculated from the 48 and 72 h Cell-
TiterGlo data, were generated by non-linear regression using the software
GraphPad Prism 7.00 for windows (GraphPad Inc).
Data availability. Crystallographic data have been deposited in the PDB, accession
codes: 5OCO, 5OCT, 5OCG, 6FA1, 6FA2, 6FA3, 6FA4. Other relevant data of this
study are included within the article and its Supplementary Information. All data
supporting the findings of this study are also available from the corresponding
author upon reasonable request.
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